FROM TREATMENT TO DISCONTINUATION: ACHIEVING SROT IN ITP PATIENTS TREATED WITH TPO-RAS IN A SINGLE-CENTER EXPERIENCE (SIE 2026) - Oct 6, 2026 - Abstract #DP157; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "Six patients received eltrombopag, ten romiplostim, and one avatrombopag. Our monocentric experience is consistent with available literature and supports the need for stan- dardized tapering strategies. Data on avatrombopag remain limited, and further studies are warranted to identify predic- tive factors for SROT"
Clinical • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura
|
|
A. Baffioni1; C. Giubbilei1; G. Giustini1; A. M. Vannucchi2; V. Carrai3
|